Navigation Links
Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting
Date:7/28/2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data will be presented on RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV) at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC on October 25-28, 2008.

Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, will present pharmacokinetic and pharmacodynamic data from the Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral presentation on October 26, 2008. Additionally, a poster will be presented on the resistance data for RDEA806 on the same day.

The presentation details are as follows:

Control Number: 4707

Title: Antiretroviral Therapy

Session Type: Slide Session

Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse

Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV

Patients

Session Day / Time: Sunday, October 26, 2008, 8:30am EDT

Presentation Time: 9:00am - 9:15am EDT

Location: Independence A (Grand Hyatt)

Control Number: 4643

Title: Antiretroviral Resistance and HIV Diagnostics

Session Type: Poster Session

Presentation Title: Resistance to RDEA806 Requires Multiple Mutations

Which Have Limited Cross-resistance to Other NNRTIs .

Session Day / Time: Sunday, October 26, 2008 11:15am EDT

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory dis
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
(Date:7/29/2015)... CITY , July 29, 2015 /PRNewswire/ - Aeterna ... today announced it has selected an optimized Erk ... milestone in the development of a new class ... MAPK pathway represents a prime target for therapeutic ... antitumor activities and survival benefits for B-Raf and ...
(Date:7/29/2015)... ... 29, 2015 , ... Rainbow Scientific, Inc. (RSI), a North ... of BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC ... a complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs ...
(Date:7/28/2015)... ... ... Xsample 530 sample changer for vials can be used with Anton Paar density ... than 12,000 mPas (internal air) up to 36,000 (external air) – and can process up ... Xsample 530 is its removable magazine, which is easily lifted off its hub and carried ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk I